Erratum  by unknown
imatinib should be considered for patients with recurrent or
unresectable MSFTs with PDGFR expression.
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ERRATUM
In the article “A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV
Non-small Cell Lung Cancer,” which appeared in volume 3 of Journal of Thoracic Oncology on pages 736–744, author
disclosures were not included. The following author disclosures should have appeared: Dr. Acres: “I am a full time
employee of Transgene. I have some Transgene shares purchased through an employee stock purchase plan” Dr. Halluard:
“I or members of my immediate family hold stock and am or have been a full or part-time employee in the organization”
Dr. Quoix: “I was paid an honorarium and travel expenses to serve as a scientific advisor for discussion of the trial with
EMEA” Dr. Bizouarne: “I am Transgene employee since 1992” Dr. Velu: “I was paid honorarium and travel expenses to
serve on the scientific advisory committee of the company that manufactures TG4040, mentioned in the manuscript.”
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